APA (7th ed.) Citation

Li, J., Zhan, X., Shao, M., Zeng, R., Li, J., Zhu, H., . . . Jing, W. Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: A prospective cohort study. Nature Portfolio.

Chicago Style (17th ed.) Citation

Li, Jixian, Xiang Zhan, Mengqing Shao, Renya Zeng, Jianan Li, Hui Zhu, Alei Feng, Zhe Yang, and Wang Jing. Osimertinib Plus Chemotherapy Versus Osimertinib for Patients with Advanced NSCLC with Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study. Nature Portfolio.

MLA (9th ed.) Citation

Li, Jixian, et al. Osimertinib Plus Chemotherapy Versus Osimertinib for Patients with Advanced NSCLC with Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study. Nature Portfolio.